What Does Wall Street Think About Bristol-Myers Squibb Company (BMY)?

Bristol-Myers Squibb Company (NYSE:BMY) is one of the best affordable healthcare stocks to buy now. On December 22, Bristol-Myers Squibb Company (NYSE:BMY) received a Buy rating from Guggenheim with a price target of $62.00.

In a separate development, Bristol-Myers Squibb Company (NYSE:BMY) announced on December 19 an agreement with the United States government for the provision of Eliquis (apixaban) for free to the Medicaid program, along with the donation of over seven tons of Eliquis active pharmaceutical ingredient (API) to ensure the resilience of the American supply chain. Eliquis is an oral anticoagulant that millions of Americans rely on daily.

Management reported that the agreement aligns with Bristol-Myers Squibb Company’s (NYSE:BMY) ongoing commitment to the advancement of cardiovascular health, enhancing patient outcomes, and collaborating with policymakers to develop solutions that simultaneously support future innovation and the lowering of costs for the healthcare system and American patients.

Bristol-Myers Squibb Company (NYSE:BMY) further reported that as part of the agreement, the company would address the four priority areas of the Administration, including making Eliquis available to Medicaid for free starting on January 1, 2026, launching new medicines with a higher balance pricing approach across developed nations, and making the historic donation of over seven tons of Eliquis API to fill the U.S. Strategic Active Ingredient Reserve at no cost to the U.S. government or taxpayers. It also includes enabling  direct-to-patient access for cash-paying patients to Sotyktu®(deucravacitinib), Zeposia®(ozanimod), Reyataz®(atazanavir), Baraclude®(entecavir), and Orencia®SC(abatacept), which allows the availability of these significant medications at around 80% discounts to the current list prices.

Bristol-Myers Squibb Company (NYSE:BMY) is a biopharmaceutical company that discovers, develops, and delivers advanced medicines for serious diseases. Its medicines fall into various therapeutic classes, including hematology, oncology, cardiovascular, immunology, and neuroscience.

While we acknowledge the potential of BMY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.